Diabetes and antibiotics: a risky mix for the heart?
NCT ID NCT07014735
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This study looks at how high blood sugar combined with a medication called moxifloxacin (an antibiotic known to affect heart rhythm) impacts the heart's electrical activity in people with insulin-resistant type 2 diabetes. Researchers will measure changes in heart tracings (ECGs) and blood markers during controlled glucose and drug challenges. The goal is to understand if these factors together increase the risk of dangerous heart rhythms, which could help guide safer medication use in diabetes patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
glucose and moxifloxacin
What this could lead to
If successful, this could help doctors identify which diabetes patients face higher heart risks from certain medications, potentially preventing dangerous heart rhythm problems.
What could go wrong
This is a small, early-phase study with only 14 participants, so results may not apply to everyone. The findings are about understanding risk, not testing a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES TYPE 2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Richmond Pharmacology Ltd.
London, SE1 1YR, United Kingdom